New drug cocktail aims to shrink liver cancer lung tumors

NCT ID NCT07482670

Not yet recruiting Disease control Sponsor: Xiangya Hospital of Central South University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two drugs—camrelizumab (an immunotherapy) and rivoceranib (a targeted therapy)—with or without local treatments like surgery or radiation can shrink tumors in people with advanced liver cancer that has spread to the lungs. About 32 participants will receive the drug combination, and some will also get local therapy. The main goal is to see how many patients have their tumors shrink significantly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: camrelizumab (an immunotherapy drug) plus rivoceranib (a targeted therapy drug)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced liver cancer that has spread to the lungs, potentially shrinking tumors and extending life.
What could go wrong: This is a small, early-phase study with only 32 participants and no comparison group. The drugs may cause side effects like immune reactions or bleeding, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA WITH PULMONARY METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATECELLULAR CARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.